Compare Sanofi SA (SNY) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while Vanguard Total Stock Market Index Fund ETF trades at $376.17. The key difference: Sanofi SA pays a 5.61% dividend while Vanguard Total Stock Market Index Fund ETF pays none, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | VTI | |
|---|---|---|
Market Cap | $104.06B | — |
Sector | Health | — |
52-Week High | $52.34 | $384.30 |
52-Week Low | $41.33 | $311.68 |
Enterprise Value | $124.09B | — |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
VTI trades at $377.60, down 0.56% with neutral technical signals. The ETF maintains broad U.S. market exposure across 3,515 stocks with a minimal 0.03% expense ratio. Recent institutional activity includes DMC Group's $794,000 investment in Q2 2026, while technical indicators show support at $375 and resistance at $379.
Long-term outlook remains positive given historical 10% annual market returns, though concentration risk exists with top ten holdings representing one-third of assets. Market sentiment favors VTI for diversification amid potential volatility, with analysts highlighting its core portfolio role for 20-year horizons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
